CRRL269 / Mayo Clinic - LARVOL DELTA

Beyond biomarkers: designer natriuretic peptides and cGMP centered therapies for cardiorenal and cardiometabolic protection in chronic heart failure. (PubMed, Intern Emerg Med) - "Recent advances in peptide engineering have enabled the development of novel designer NPs, including Cenderitide, aimed at restoring and enhancing their signalling...Additional engineered peptides, including ANX042, MANP, and CRRL269, as well as complementary approaches targeting the cGMP pathway, such as soluble guanylate cyclase (sGC) stimulators, neprilysin inhibitors, and GC-A positive allosteric modulators, are further expanding the therapeutic potential of NP-centred therapies. Beyond cardiovascular effects, NPs also influence metabolic regulation and renal function, highlighting their relevance in cardiometabolic disease. Collectively, these developments support a shift from the use of NPs solely as biomarkers toward their emerging role as therapeutic targets and agents in the treatment of CHF."

Biomarker • Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

CRRL269: A Novel Particulate Guanylyl Cyclase A Receptor Peptide Activator For Acute Kidney Injury. (PubMed, Circ Res) - "Our study supports developing CRRL269 as a novel renocardiac protective agent for AKI treatment."

Biomarker • Journal